Cancer Prevention registers $28.75 million of common stock for IPO

Aegis Capital helps finance clinical trials, research and development

By Devika Patel

Knoxville, Tenn., Dec. 23 – Cancer Prevention Pharmaceuticals, Inc. will price its initial public sale of common stock with a 45-day over-allotment option, according to a Form S-1 filed Wednesday with the Securities and Exchange Commission. The company has registered up to $28.75 million of stock.

Aegis Capital Corp. is the bookrunner.

Proceeds would be used for clinical trials, research and development, working capital and other general corporate purposes.

The biopharmaceutical company is based in Tucson, Ariz. It expects its stock to be listed on the New York Stock Exchange.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.